Opioid Abuse-Deterrence Labeling May Be A Long Way Off After Panel Rejects Validity Of Broad Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling should be specific, such as a claim for injection-resistance, committee members tell FDA.
You may also be interested in...
FDA Takes Advisory Committee Off Life Support, Adds Analgesics To Title
The Anesthetics and Life Support Drugs Advisory Committee discussed analgesics at 11 of 14 meetings during the past four years, anesthetics at three, and life support drugs at none.
FDA Takes Advisory Committee Off Life Support, Adds Analgesics To Title
The Anesthetics and Life Support Drugs Advisory Committee discussed analgesics at 11 of 14 meetings during the past four years, anesthetics at three, and life support drugs at none.
Pfizer Will Study Oxecta Abuse/Misuse Potential Post-Market
FDA okays the opioid, which contains abuse-resistant components, with labeling about a study that found the drug less likeable than immediate-release oxycodone.